CRNX - Crinetics Pharmaceuticals, Inc.
| Previous Close | 23.24 |
| Open | 23.50 |
| Bid | 23.55 x 900 |
| Ask | 23.70 x 1200 |
| Day's Range | 23.09 - 24.68 |
| 52 Week Range | 19.23 - 42.00 |
| Volume | 48,161 |
| Avg. Volume | 60,826 |
| Market Cap | 573.041M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.73 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.50 |
- GlobeNewswire•last month
Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the initiation of a Phase 1, double-blind, randomized, placebo-controlled, single- and multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CRN01941 in healthy volunteers. CRN01941 is an oral nonpeptide somatostatin receptor subtype 2 (sst2) biased agonist designed for the treatment of neuroendocrine tumors (NETs) that originate from neuroendocrine cells commonly found in the gut, lung, or pancreas.
- GlobeNewswire•last month
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, May 13, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Insider Monkey•2 months ago
Here’s What Hedge Funds Think About Crinetics Pharmaceuticals, Inc. (CRNX)
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- GlobeNewswire•3 months ago
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the dosing of the first patients in the ACROBAT EVOLVE and EDGE trials for CRN00808 in patients with acromegaly. EVOLVE is a double-blind, placebo-controlled, randomized withdrawal study designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, in patients with acromegaly that are responders to octreotide LAR or lanreotide depot monotherapy. EDGE is an open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808 in patients with acromegaly whose disease is inadequately controlled by octreotide LAR or lanreotide depot alone.
- GlobeNewswire•3 months ago
Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning
SAN DIEGO, March 18, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire•3 months ago
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019
SAN DIEGO, March 14, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire•3 months ago
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
SAN DIEGO, March 13, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire•4 months ago
Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 21, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Benzinga•5 months ago
Top 5 Small-Cap Winners And Losers, Week Of Jan. 7
In today’s round-up of the previous week’s top five shakers and fakers (i.e. winners and losers,), we see some major jumps or drops depending on how well company announcements were received. For some, ...
- American City Business Journals•6 months ago
At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.
- GlobeNewswire•6 months ago
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 02, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire•7 months ago
New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•7 months ago
Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference
SAN DIEGO, Nov. 20, 2018 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire•7 months ago
Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 13, 2018 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- ACCESSWIRE•11 months ago
Today’s Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Shares of CTI Biopharma tanked nearly 44% yesterday while shares of Crinetics Pharmaceuticals exploded 44%. The former announced an update from an FDA meeting regarding the company's investigational drug pacritinib. Per FDA feedback, the company will now have to conduct a Phase 3 trial.
